Examkin

Question

Difficulty: MediumInfectious Diseases

A 31-year-old male is admitted to the general medical ward for evaluation of severe right arm pain and persistent fevers. He reports a history of injection drug use. His vital signs on admission include a temperature of 39.1°C (102.4°F), blood pressure of 112/70 mm Hg, and a heart rate of 115/min. Physical examination of the right upper extremity reveals a 4-cm area of fluctuance with overlying warmth and marked erythema. Initial blood cultures are obtained, and he is empirically commenced on intravenous vancomycin and piperacillin-tazobactam. An echocardiogram shows structurally normal valves with no vegetations. Over the subsequent two days, the patient defervesces and the localized arm erythema improves. The laboratory reports that the admission blood cultures are positive in all bottles for Staphylococcus aureus. Antimicrobial susceptibility testing demonstrates resistance to penicillin but susceptibility to oxacillin, cefazolin, daptomycin, and vancomycin. Which of the following is the most appropriate modification to his antimicrobial therapy?

  1. Replace the current regimen with intravenous cefazolinAnswer
  2. B
    Halt piperacillin-tazobactam but continue intravenous vancomycin
  3. C
    Halt vancomycin but continue intravenous piperacillin-tazobactam
  4. D
    Replace the current regimen with intravenous daptomycin
  5. E
    Augment the current regimen by adding intravenous gentamicin

Answer

Replace the current regimen with intravenous cefazolin
The patient has methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. For MSSA infections, targeted therapy with a narrow-spectrum, anti-staphylococcal beta-lactam (such as cefazolin, nafcillin, or oxacillin) is the definitive standard of care. These agents are significantly superior to vancomycin for MSSA, demonstrating faster bacterial clearance rates, lower associated mortality, and reduced toxicity. Therefore, the most appropriate next step is to discontinue the broad-spectrum empiric regimen and initiate intravenous cefazolin.

Step-by-Step Solution

1
Identify the specific pathogen and its susceptibility profile from the laboratory results.
The pathogen is identified as methicillin-susceptible Staphylococcus aureus (MSSA), as it is susceptible to oxacillin and cefazolin.
Determining the specific organism and its resistance pattern is required to transition from empiric to targeted therapy.
2
Evaluate the patient's current empiric antimicrobial regimen.
The patient is receiving broad-spectrum coverage with vancomycin (for MRSA) and piperacillin-tazobactam (for Pseudomonas and anaerobes).
Empiric therapy is designed to cover a wide range of potential pathogens before culture results are available, but must be de-escalated once susceptibilities are known.
3
Select the optimal targeted definitive therapy for the identified pathogen.
Intravenous cefazolin is selected, and the empiric broad-spectrum agents are safely discontinued.
Anti-staphylococcal beta-lactams (e.g., cefazolin, nafcillin) provide superior clinical outcomes, faster bacterial clearance, and lower mortality for MSSA bacteremia compared to vancomycin.

Key Concept

For methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, anti-staphylococcal beta-lactams (such as cefazolin or nafcillin) are superior to vancomycin and should be used as targeted definitive therapy to optimize patient outcomes and adhere to antimicrobial stewardship.
Rate this question

Topics

Infectious Diseases

More questions from this topic